These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 22898871

  • 1. Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence.
    Drullion C, Trégoat C, Lagarde V, Tan S, Gioia R, Priault M, Djavaheri-Mergny M, Brisson A, Auberger P, Mahon FX, Pasquet JM.
    Cell Death Dis; 2012 Aug 16; 3(8):e373. PubMed ID: 22898871
    [Abstract] [Full Text] [Related]

  • 2. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
    Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Esterbauer H, Valent P.
    Cancer Res; 2005 Oct 15; 65(20):9436-44. PubMed ID: 16230407
    [Abstract] [Full Text] [Related]

  • 3. BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells.
    Sharma A, Singh K, Mazumder S, Hill BT, Kalaycio M, Almasan A.
    Cell Death Dis; 2013 May 16; 4(5):e628. PubMed ID: 23681223
    [Abstract] [Full Text] [Related]

  • 4. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia.
    Shao S, Li S, Qin Y, Wang X, Yang Y, Bai H, Zhou L, Zhao C, Wang C.
    Int J Oncol; 2014 May 16; 44(5):1661-8. PubMed ID: 24585095
    [Abstract] [Full Text] [Related]

  • 5. H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib.
    Dong Y, Xiong M, Duan L, Liu Z, Niu T, Luo Y, Wu X, Xu C, Lu C.
    Apoptosis; 2014 Aug 16; 19(8):1281-92. PubMed ID: 24830786
    [Abstract] [Full Text] [Related]

  • 6. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
    Elzinga BM, Nyhan MJ, Crowley LC, O'Donovan TR, Cahill MR, McKenna SL.
    Am J Hematol; 2013 Jun 16; 88(6):455-62. PubMed ID: 23440701
    [Abstract] [Full Text] [Related]

  • 7. Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines.
    Belloc F, Moreau-Gaudry F, Uhalde M, Cazalis L, Jeanneteau M, Lacombe F, Praloran V, Mahon FX.
    Cancer Biol Ther; 2007 Jun 16; 6(6):912-9. PubMed ID: 17538248
    [Abstract] [Full Text] [Related]

  • 8. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
    Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC, Kimura S, Ottmann OG, Druker BJ, Villunger A, Roberts AW, Strasser A.
    Proc Natl Acad Sci U S A; 2006 Oct 03; 103(40):14907-12. PubMed ID: 16997913
    [Abstract] [Full Text] [Related]

  • 9. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X, Zhao H, Li Y, Fan J, Sun Y, Wang S, Wang Z, Song P, Ju D.
    Autophagy; 2015 Oct 03; 11(2):355-72. PubMed ID: 25701353
    [Abstract] [Full Text] [Related]

  • 10. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K, Mahon FX, Josselin M, Jeanneteau M, Turcq B, Belloc F.
    Exp Hematol; 2012 May 03; 40(5):367-78.e2. PubMed ID: 22240609
    [Abstract] [Full Text] [Related]

  • 11. Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells.
    Yu Y, Yang L, Zhao M, Zhu S, Kang R, Vernon P, Tang D, Cao L.
    Leukemia; 2012 Aug 03; 26(8):1752-60. PubMed ID: 22395361
    [Abstract] [Full Text] [Related]

  • 12. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.
    Kiyota M, Kuroda J, Yamamoto-Sugitani M, Shimura Y, Nakayama R, Nagoshi H, Mizutani S, Chinen Y, Sasaki N, Sakamoto N, Kobayashi T, Matsumoto Y, Horiike S, Taniwaki M.
    Apoptosis; 2013 Nov 03; 18(11):1437-1446. PubMed ID: 23851982
    [Abstract] [Full Text] [Related]

  • 13. Activin A induction of erythroid differentiation sensitizes K562 chronic myeloid leukemia cells to a subtoxic concentration of imatinib.
    Huang YW, Lee WH, Tsai YH, Huang HM.
    Am J Physiol Cell Physiol; 2014 Jan 01; 306(1):C37-44. PubMed ID: 24088895
    [Abstract] [Full Text] [Related]

  • 14. Imatinib induces autophagy through BECLIN-1 and ATG5 genes in chronic myeloid leukemia cells.
    Can G, Ekiz HA, Baran Y.
    Hematology; 2011 Mar 01; 16(2):95-9. PubMed ID: 21418740
    [Abstract] [Full Text] [Related]

  • 15. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
    Dai Y, Rahmani M, Corey SJ, Dent P, Grant S.
    J Biol Chem; 2004 Aug 13; 279(33):34227-39. PubMed ID: 15175350
    [Abstract] [Full Text] [Related]

  • 16. A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib.
    Augis V, Airiau K, Josselin M, Turcq B, Mahon FX, Belloc F.
    PLoS One; 2013 Aug 13; 8(11):e78582. PubMed ID: 24223824
    [Abstract] [Full Text] [Related]

  • 17. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
    Liu JH, Liu CC, Yen CC, Gau JP, Wang WS, Tzeng CH.
    Int J Cancer; 2009 Jul 01; 125(1):71-7. PubMed ID: 19291793
    [Abstract] [Full Text] [Related]

  • 18. The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells.
    Bozkurt S, Özkan T, Özmen F, Baran Y, Sunguroğlu A, Kansu E.
    Hematology; 2013 Jul 01; 18(4):217-23. PubMed ID: 23394612
    [Abstract] [Full Text] [Related]

  • 19. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
    San José-Eneriz E, Agirre X, Jiménez-Velasco A, Cordeu L, Martín V, Arqueros V, Gárate L, Fresquet V, Cervantes F, Martínez-Climent JA, Heiniger A, Torres A, Prósper F, Roman-Gomez J.
    Eur J Cancer; 2009 Jul 01; 45(10):1877-89. PubMed ID: 19403302
    [Abstract] [Full Text] [Related]

  • 20. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijusufovic E, Cerny-Reiterer S, Mayerhofer M, Pickl WF, Sillaber C, Valent P.
    Cancer Res; 2010 Feb 15; 70(4):1513-23. PubMed ID: 20145140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.